Compare TEO & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TEO | ALKS |
|---|---|---|
| Founded | 1979 | 1987 |
| Country | Argentina | Ireland |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 4.7B |
| IPO Year | N/A | 1991 |
| Metric | TEO | ALKS |
|---|---|---|
| Price | $10.83 | $31.66 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | $9.60 | ★ $42.85 |
| AVG Volume (30 Days) | 202.1K | ★ 1.8M |
| Earning Date | 02-26-2026 | 02-11-2026 |
| Dividend Yield | ★ 2.84% | N/A |
| EPS Growth | N/A | ★ 2.44 |
| EPS | N/A | ★ 2.02 |
| Revenue | ★ $4,379,419,485.00 | $1,521,338,000.00 |
| Revenue This Year | $91.61 | N/A |
| Revenue Next Year | $10.21 | $22.50 |
| P/E Ratio | ★ N/A | $15.72 |
| Revenue Growth | ★ 18.69 | 1.08 |
| 52 Week Low | $6.43 | $25.17 |
| 52 Week High | $13.54 | $36.45 |
| Indicator | TEO | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 39.90 | 70.93 |
| Support Level | $10.71 | $28.93 |
| Resistance Level | $11.73 | $31.96 |
| Average True Range (ATR) | 0.39 | 0.94 |
| MACD | -0.06 | 0.38 |
| Stochastic Oscillator | 12.50 | 94.17 |
Telecom Argentina SA offers its customers quadruple play services, combining mobile telephony services, cable television services, Internet services and fixed telephony services. It also provides other telephone-related services such as international long-distance and wholesale services, data transmission and IT solutions outsourcing and install, operate and develop cable television and data transmission services. The company provides services in Argentina (mobile, cable television, Internet and fixed and data services), Paraguay (mobile, Internet and satellite TV services), Uruguay (cable television services), the United States (fixed wholesale services) and Chile (Cybersecurity services and products).
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.